Publications by authors named "Steven Bai"

Claim this Profile
S
Statistical power considerations in the use of win ratio in cardiovascular outcome trials.
Bang Wang, Dali Zhou, Jialu Zhang, Yoonhee Kim, Ling-Wan Chen, Steven Bai

Contemp Clin Trials· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation on conditional restricted mean survival time with counting process.
Junshan Qiu, Dali Zhou, H M Jim Hung, John Lawrence, Steven Bai

J Biopharm Stat· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation on conditional restricted mean survival time with counting process.
Junshan Qiu, Ennan Gu, Dali Zhou, John Lawrence, Steven Bai

J Biopharm Stat· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and monitoring of survival trials in complex scenarios.
Xiaodong Luo, Xuezhou Mao, Xun Chen, Junshan Qiu, Steven Bai

Stat Med· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weighted win loss approach for analyzing prioritized outcomes.
Xiaodong Luo, Junshan Qiu, Steven Bai, Hong Tian

Stat Med· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
Paul J Gilligan, Todd Clarke, Liqi He, Snjezana Lelas, Yu-Wen Li, Steven Bai

J Med Chem· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.
Jeffrey G Varnes, Dean A Wacker, Donald J P Pinto, Michael J Orwat, Jay P Theroff, Steven Bai

Bioorg Med Chem Lett· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors.
Jeffrey G Varnes, Dean A Wacker, Irina C Jacobson, Mimi L Quan, Christopher D Ellis, Steven Bai

Bioorg Med Chem Lett· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
Donald J P Pinto, Michael J Orwat, Mimi L Quan, Qi Han, Robert A Galemmo, Steven Bai

Bioorg Med Chem Lett· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).
James R Pruitt, Donald J P Pinto, Robert A Galemmo, Richard S Alexander, Karen A Rossi, Steven Bai

J Med Chem· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis